BioSpace News Archive

Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Pasit Phiasivongsa, Ph.D., as senior vice president, pharmaceutical development

BRAINBox Solutions today announced the initial closing on a $23 million Series A financing to support the clinical development of the company’s BRAINBox TBI (Traumatic Brain Injury) Test to aid both in the diagnosis and prognosis of mild TBI (concussion).

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”) today announced that first-in-human data from the first dose cohort of the Phase 1 portion of the Actimab-A venetoclax Phase 1/2 combination trial in patients with relapsed or refractory Acute Myeloid Leukemia (AML) were presented at the 62nd American Society of Hematology (ASH) annual meeting.

BIOREM Inc. (TSXV: BRM) (“Biorem” or “the Company”) today announced the successful completion of two research projects for the mitigation of volatile organic compounds from complex industrial gas emissions. Both projects were to assess and compare the efficacy of BIOREM’s enhanced biological processes against legacy

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Company’s website, www.alnylam.com , on December 15 and 16, 2020. In addition to presentations from Alnylam senior leaders, the event will include presentations from the following guest speakers: Akshay Desai, M.D.,

EZaccessMD is the first and only mobile, employer-based subscription telehealth provider that brings rapid diagnostics right to the patient’s home. Today, the company announced an additional exclusive offering – rapid mobile in-home COVID-19 testing.

CV Sciences, Inc., a preeminent supplier and manufacturer of hemp cannabidiol products, announced that it has entered into a Common Stock Purchase Agreement with Tumim Stone Capital, LLC.

Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, yesterday reported initial data from an ongoing proof-of-concept clinical trial evaluating the safety and efficacy of OTL-201, an investigational ex vivo autologous hematopoietic stem cell (HSC) gene therapy being studied for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA, also known as Sanfilippo syndrome type A). The data were presented as part of an oral pres

Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that its Investigational New Drug Application (IND) to study the use of CERC-007 to treat relapsed or refractory multiple myeloma (MM) has been accepted by the United States Food and Drug Administration (FDA) and is now open. The first study w

- Reduction of marrow blasts observed in all evaluable patients - - Marrow complete response observed in 2 patients - - Management to host virtual KOL event today, Tuesday, December 8 at 8:00 a.m. ET -